Late results of the HyPro study (Hypofractionation in Prostate cancer patients) and clinical implications

Marjolein van Os Os,, research technologist Erasmus MC Cancer Institute, Rotterdam, The Netherlands EORTC ROG RTTRTT-meeting Prague, March 3 2016

Late results of the HyPro study


Study design
HyPro study in clinical practice; dose planning, imaging and scoring of toxicity
Adjustments during trial
Results: toxicity and survival
Conclusion
Now what?

1

Study design
Randomized controlled trial for intermediate and high risk Prostate cancer patients
3 risk groups according to seminal vesicle involvement Gleason

T1 - T3a

T3b, T4

score

2-6

PSA

PSA

PSA

0-≤4

4 -